"the relaxivity of gadofosveset is higher than other commercially-available gadolinium contrast agents (r1 = 7.3 for gadoxetate disodium (Eovist), the next highest gadolinium chelate)."
"In the United States, gadofosveset is FDA-approved only for use in aortoiliac disease, with other uses being off-label. It does not have a role in hepatic imaging."
"In the United States, gadofosveset is FDA-approved only for use in aortoiliac disease, with other uses being off-label. It does not have a role in hepatic imaging."
"In the United States, gadofosveset is FDA-approved only for use in aortoiliac disease, with other uses being off-label. It does not have a role in hepatic imaging."